Syndax Pharmaceuticals, Inc.
Syndax is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. For more information, visit www.syndax.com or follow the Company on X and LinkedIn.